Detailansicht

Wissensnetz

Person

Markus Ries (1971-)

Arzt

Name	Markus Ries
Zeit	1971- (Lebensdaten)
Ort	Bad Hersfeld (Wirkungsort) Heidelberg (Wirkungsort) Deutschland
Akademischer Grad bzw. Titel	Prof. Dr. rer. nat., Dr. med. M.H.S (Duke Univ., USA)
Beruf	Arzt (charakteristischer Beruf)
Beziehung	Klinikum Heidelberg
Weitere Angaben	Arzt, Klinik Kinderheilkunde I, Zentrum für Kinder- und Jugendmedizin Heidelberg, Universitätsklinikum Heidelberg
Quelle	AM
Datensatztyp	Person
GND-Nummer	136385338
Datensatz-ID	136385338
Beteiligt an alle anzeigen Towards better preparedness for future catastrophes : lessons learned from civil-military pandemic response Towards Better Preparedness for Future Catastrophes : Lessons Learned from Civil-Military Pandemic Response A Cross-Sectional Analysis of Registered Studies on the Promising Dipeptide Carnosine Orphan drug development in alpha-1 antitypsin deficiency Missing trial results: analysis of the current publication rate of studies in pediatric dialysis from 2003 to 2020 The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database Cross-sectional quantitative analysis of the natural history of TUBA1A and TUBB2B tubulinopathies Challenging behavior in mucopolysaccharidoses types I–III and day-to-day coping strategies: a cross sectional explorative study Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.” - a cross-sectional analysis Clinical characteristics of 248 patients with Krabbe disease: quantitative natural history modeling based on published cases Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis A cross-sectional quantitative analysis of the natural history of free sialic acid storage disease—an ultra-orphan multisystemic lysosomal storage disorder Critical appraisal of genotype assessment in molybdenum cofactor deficiency Roscoe O. Brady, MD Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016) Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act Skin-impedance in Fabry Disease: A prospective, controlled, non-randomized clinical study Biochemical markers of lipid storage and vasculopathy in Fabry disease

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Markus Ries (1971-)

Towards better preparedness for future catastrophes : lessons learned from civil-military pandemic response

Towards Better Preparedness for Future Catastrophes : Lessons Learned from Civil-Military Pandemic Response

A Cross-Sectional Analysis of Registered Studies on the Promising Dipeptide Carnosine

Orphan drug development in alpha-1 antitypsin deficiency

Missing trial results: analysis of the current publication rate of studies in pediatric dialysis from 2003 to 2020

The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database

Cross-sectional quantitative analysis of the natural history of TUBA1A and TUBB2B tubulinopathies

Challenging behavior in mucopolysaccharidoses types I–III and day-to-day coping strategies: a cross sectional explorative study

Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.” - a cross-sectional analysis

Clinical characteristics of 248 patients with Krabbe disease: quantitative natural history modeling based on published cases

Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis

A cross-sectional quantitative analysis of the natural history of free sialic acid storage disease—an ultra-orphan multisystemic lysosomal storage disorder

Critical appraisal of genotype assessment in molybdenum cofactor deficiency

Roscoe O. Brady, MD

Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016)

Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act

Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders

Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act

Skin-impedance in Fabry Disease: A prospective, controlled, non-randomized clinical study

Biochemical markers of lipid storage and vasculopathy in Fabry disease